|
SU5416 in Treating Patients With Metastatic or Locally Recurrent Colorectal Cancer Clinical Trials References presented on Clinical Trials Search isn't meant to be a substitute for proven healthcare advice, trips or professional assistance using a genuine physician. We are not docs. Always confer with your physician about SU5416 in Treating Patients With Metastatic or Locally Recurrent Colorectal Cancer conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. SU5416 in Treating Patients With Metastatic or Locally Recurrent Colorectal Cancer Clinical research trials and SU5416 in Treating Patients With Metastatic or Locally Recurrent Colorectal Cancer healthcare trials happen in hundreds of localities throughout the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the potency of new drugs. The propose of the studies / projects is to answer particular human health questions. Clinical trials are a popular way for mDs, government agencies, and private sector companies to detect cures for all sorts of conditions, such as SU5416 in Treating Patients With Metastatic or Locally Recurrent Colorectal Cancer. SU5416 in Treating Patients With Metastatic or Locally Recurrent Colorectal Cancer Clinical Trials and other clinical trials allow volunteers to acquire healthcare treatment choices before they are available to the general public. Some times the subjects recieve professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a SU5416 in Treating Patients With Metastatic or Locally Recurrent Colorectal Cancer clinical trial. Subjects frequently obtain the most expert healthcare possible for their SU5416 in Treating Patients With Metastatic or Locally Recurrent Colorectal Cancer condition. Risks are a reality, nevertheless, and can include more or frequent doctor trips, medical risks (possibly life-threatening), and/or the treatment being uneffective. Trials are federally governed with stern guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "S" Clinical Trials Conditions > SU5416 in Treating Patients With Metastatic or Locally Recurrent Colorectal Cancer  SU5416 in Treating Patients With Metastatic or Locally Recurrent Colorectal Cancer
SU5416 in Treating Patients With Metastatic or Locally Recurrent Colorectal Cancer
For Condition: adenocarcinoma of the rectum,recurrent rectal cancer,adenocarcinoma of the colon,stage 3 colon cancer,recurrent colon cancer,stage 3 rectal cancer,Stage 4 rectal cancer,stage 4 colon cancer
Status: No longer recruiting
Sponsor(s): National Cancer Institute (NCI) , University of Chicago Cancer Research Center
Synopsis: RATIONALE: SU5416 may stop the growth of colorectal cancer by stopping blood flow to the tumor. PURPOSE: Phase II trial to study the effectiveness of SU5416 in treating patients who have metastatic or locally recurrent colorectal cancer.
Details: OBJECTIVES: I. Determine the objective response rate and disease stabilization rates of patients with previously treated metastatic or locally recurrent colorectal cancer treated with SU5416. II. Determine the median and overall survival and time to progression in this patient population receiving this treatment. III. Determine the toxicity of SU5416 in these patients. PROTOCOL OUTLINE: This is a multicenter study. Patient receive SU5416 IV over 60 minutes twice weekly for 4 weeks. Treatment continues for a minimum of 2 courses in the absence of unacceptable toxicity or disease progression. Patients are followed every 2 weeks for 4 weeks. PROJECTED ACCRUAL: A total of 17-37 patients will be accrued for this study within 12-18 months.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders:
Protocol Entry Criteria: PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- - Histologically confirmed metastatic or locally recurrent adenocarcinoma of the colon or rectum - Progressive disease as defined by new or progressive radiologic lesions - Measurable disease; At least 1 dimension as at least 20 mm with conventional techniques or at least 10 mm with spiral CT scan; Lesions seen on colonoscopic examination or barium studies, bone metastases, CNS lesions, CEA levels and ascites are not considered measurable - Lesion accessible for biopsy which is not within prior radiation port - Known history of CNS metastasis allowed if patients have had treatment, are neurologically stable, and do not require oral or intravenous steroids or anticonvulsants, provided brain scan (CT or MRI) shows absence of active or residual disease; If neurologic signs or symptoms suggestive of CNS metastasis, negative brain scan required --Prior/Concurrent Therapy-- - Biologic therapy: Not specified - Chemotherapy: No more than 2 prior chemotherapy regimens for metastatic disease; At least 4 weeks since prior chemotherapy; No concurrent chemotherapy; No other concurrent investigational antineoplastic drugs - Endocrine therapy: See Disease Characteristics - Radiotherapy: See Disease Characteristics; No prior radiotherapy to only site of measurable disease; At least 4 weeks since prior radiotherapy and recovered; No concurrent radiotherapy - Surgery: Not specified - Other: At least 30 days since other prior investigational drugs --Patient Characteristics-- - Age: 18 and over - Performance status: WHO 0-2 - Life expectancy: At least 12 weeks - Hematopoietic: WBC at least 3,000/mm3; Platelet count at least 75,000/mm3 - Hepatic: Bilirubin no greater than 1.5 mg/dL; Transaminases no greater than 2.5 times upper limit of normal - Renal: Creatinine no greater than 1.5 mg/dL OR Creatinine clearance at least 60 mL/min - Cardiovascular: No uncompensated coronary artery disease; No history of myocardial infarction or severe/unstable angina within past 6 months; No severe peripheral vascular disease associated with diabetes mellitus; No deep venous or arterial thrombosis within past 3 months - Pulmonary: No pulmonary embolism within past 3 months - Negative pregnancy test; Fertile patients must use effective contraception; No other significant uncontrolled underlying medical or psychiatric illness; No serious active infections; No concurrent second malignancy except for nonmelanoma skin cancer or carcinoma in situ of the cervix unless completed therapy and considered to be at less than 30% risk of relapse; No history of severe allergic or anaphylactic reactions to paclitaxel or docetaxel
Total Enrollment:
Location and Contact Information:
Overall Study Official:
HedyKindler, Study Chair, University of Chicago Cancer Research Center
Fort Wayne Medical Oncology and Hematology, Inc.
Ft. Wayne, Indiana, 46885-5099
United States
Central Illinois Hematology Oncology Center
Springfield, Illinois, 62701
United States
Michiana Hematology/Oncology P.C.
South Bend, Indiana, 46617
United States
Oncology/Hematology Associates of Central Illinois, P.C.
Peoria, Illinois, 61602
United States
Cancer Care Specialists of Central Illinois, S.C.
Decatur, Illinois, 62526
United States
Louis A. Weiss Memorial Hospital
Chicago, Illinois, 60640
United States
University of Chicago Cancer Research Center
Chicago, Illinois, 60637
United States
University of Illinois at Chicago
Chicago, Illinois, 60612
United States
Evanston Northwestern Health Care
Evanston, Illinois, 60201
United States
Division of Hematology/Oncology
Park Ridge, Illinois, 60068
United States
Additional Information:
Study ID Numbers: CDR0000068009; NCI-52,UCCRC-NCI-52
Study Start Date: August 2000
Record last reviewed: May 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00006001
Other Stage 3 Rectal Cancer Studies:
1. NB1011 in Treating Patients With Metastatic or Recurrent Colorectal Cancer
2. Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer
3. Hepatic Arterial Infusion With Floxuridine and Systemic Irinotecan After Surgery in Treating Patients With Hepatic (Liver) Metastases From Colorectal Cancer
4. FR901228 in Treating Patients With Advanced Colorectal Cancer That Has Progressed After a Previous Fluorouracil-Containing Regimen
5. Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Related Studies:
Other stage 3 rectal cancer Clinical Trials
Other Indiana Clinical Trials
Other Ft. Wayne Clinical Trials
SU5416 in Treating Patients With Metastatic or Locally Recurrent Colorectal Cancer
|
|
|
|
|
|
|
|
